Express Pharma

Takeda to go forward with annual performance appraisals, rewards

0 355

Selected to lead Takeda’s business in India this April, Koki Sato, GM, Takeda India finds himself working remotely from Ukraine, his previous posting, with his new team in India. In spite of the disruptions to the business cycle due to the COVID-19 pandemic, he indicates to Viveka Roychowdhury that Takeda has decided to go forward with their annual performance appraisal and rewards as usual, as well as hiring plans in India.

You have recently taken over as India head of Takeda but are working remotely due to the pandemic. What are your strategic objectives for this year, besides dealing with COVID-19?

Ever since my appointment, there has been travel restrictions that has led me to work remotely with our team. In the last couple of weeks, I have been working closely with the leadership and the team to understand the people and business priorities in India.

At Takeda, patients are at the core of all our decisions, and it is important for us to enhance patients’ access to innovative medicines. We are working relentlessly to bring the best in class therapies to them. We have a strong Access to Medicine (AtM) strategy that is fundamental to our philosophy to address the broader structural barriers that prevent patients in underserved communities from receiving the care and treatment they deserve.

With my appointment, I will look at supporting the team in India to furth